Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

被引:81
作者
Lutz, JE
Clemons, KV
Aristizabal, BH
Stevens, DA
机构
[1] SANTA CLARA VALLEY MED CTR,DIV INFECT DIS,DEPT MED,SAN JOSE,CA 95128
[2] CALIF INST MED RES,SAN JOSE,CA 95128
[3] STANFORD UNIV,DEPT MED,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305
关键词
D O I
10.1128/AAC.41.7.1558
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
SCH 56592 (SCH) is a new triazole antifungal with a broad spectrum of activity, In vitro susceptibility testing against five strains of Coccidioides immitis revealed MICs from 0.39 to 3.13 mu g/ml and minimal fungicidal concentrations from 1.56 to 3.13 mu g/ml. A murine model of systemic coccidioidomycosis was established in female CD-I mice, Groups received either no treatment or oral therapy with fluconazole at 10 or 100 mg/kg of body weight; itraconazole at 10 or 100 mg/kg; SCH at 0.5, 2, 10, or 25 mg/kg; or its methylcellulose diluent alone, Therapy began 2 days postinfection and continued once daily for 19 days, Surviving mice were euthanized 49 days postinfection, and infectious burdens were determined by culture, All drugs were superior to no-treatment or diluent-treatment controls (P < 0.001) in prolonging survival hut were not significantly different from one another, Itraconazole at 100 mg/kg was superior to fluconazole in reduction of CFU in the spleen, liver, and lung (P < 0.01 to 0.001), SCH at 0.5 mg/kg was superior to either fluconazole or itraconazole at 10 mg/kg in reduction of CFU in all three organs (P < 0.05 to 0.001). SCH at 2 mg/kg was not significantly different from itraconazole at 100 mg/kg in all three organs. SCH at 10 and 25 mg/kg was superior to either dose of fluconazole or itraconazole in all three organs (P < 0.05 to 0.001), In terms of reduction of CFU, SCH was greater than or equal to 200-fold as potent as fluconazole and greater than or equal to 50-fold as potent as itraconazole. There was a clear dose-responsive relationship for SCH in each of the organs, It is noteworthy that SCH effected cures (no detectable C. immitis in any organ) in 1 of 9, 6 of 10, or 9 of 9 surviving mice in animals given 2, 10, or 25 mg/kg, respectively, Neither fluconazole nor itraconazole cured any survivor, SCH has potent, fungicidal activity in vivo against C. immitis. It should be considered for clinical trials in patients with coccidioidomycosis.
引用
收藏
页码:1558 / 1561
页数:4
相关论文
共 19 条
[1]  
CACCIAPUOTI A, 1995, 35 INT C ANT AG CHEM, P124
[2]  
*CDC, 1994, MMWR-MORBID MORTAL W, V43, P421
[3]   ACTIVITIES OF THE TRIAZOLE SCH-51048 AGAINST COCCIDIOIDES-IMMITIS IN-VITRO AND IN-VIVO [J].
CLEMONS, KV ;
HOMOLA, ME ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1169-1172
[4]   COMPARATIVE EFFICACY OF AMPHOTERICIN-B COLLOIDAL DISPERSION AND AMPHOTERICIN-B DEOXYCHOLATE SUSPENSION IN TREATMENT OF MURINE COCCIDIOIDOMYCOSIS [J].
CLEMONS, KV ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) :1829-1833
[5]   SYSTEMIC COCCIDIOIDES-IMMITIS INFECTION IN NUDE AND BEIGE MICE [J].
CLEMONS, KV ;
LEATHERS, CR ;
LEE, KW .
INFECTION AND IMMUNITY, 1985, 47 (03) :814-821
[6]   EFFICACIES OF AMPHOTERICIN-B LIPID COMPLEX (ABLC) AND CONVENTIONAL AMPHOTERICIN-B AGAINST MURINE COCCIDIOIDOMYCOSIS [J].
CLEMONS, KV ;
STEVENS, DA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 (03) :353-363
[7]   EFFICACY OF SCH39304 AND FLUCONAZOLE IN A MURINE MODEL OF DISSEMINATED COCCIDIOIDOMYCOSIS [J].
CLEMONS, KV ;
HANSON, LH ;
PERLMAN, AM ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :928-930
[8]  
CLEMONS KV, 1994, J MED VET MYCOL, V32, P323
[9]   Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? [J].
Dewsnup, DH ;
Galgiani, JN ;
Graybill, JR ;
Diaz, M ;
Rendon, A ;
Cloud, GA ;
Stevens, DA .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (03) :305-+
[10]   COCCIDIOIDOMYCOSIS - NEW ASPECTS OF EPIDEMIOLOGY AND THERAPY [J].
EINSTEIN, HE ;
JOHNSON, RH .
CLINICAL INFECTIOUS DISEASES, 1993, 16 (03) :349-356